CLBT Cellebrite DI Ltd.

Nasdaq cellebrite.com


$ 19.73 $ 0.80 (4.23 %)    

Thursday, 13-Nov-2025 09:49:08 EST
QQQ $ 614.14 $ -3.54 (-0.57 %)
DIA $ 481.96 $ 0.49 (0.1 %)
SPY $ 678.54 $ -1.94 (-0.29 %)
TLT $ 89.85 $ 0.05 (0.06 %)
GLD $ 385.52 $ -1.76 (-0.45 %)
$ 15.97
$ 18.96
$ 19.70 x 10
$ 19.80 x 60
$ 18.47 - $ 19.80
$ 13.10 - $ 26.30
1,613,689
na
3.82B
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-maintains-buy-on-cellebrite-di-raises-price-target-to-24

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $22 to $24.

 jp-morgan-maintains-overweight-on-cellebrite-di-raises-price-target-to-23

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $20 t...

 lake-street-maintains-buy-on-cellebrite-di-lowers-price-target-to-22

Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to...

 needham-maintains-buy-on-cellebrite-di-lowers-price-target-to-18

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.

 cellebrite-di-sees-q3-sales-121000m-126000m-vs-124357m-est

Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $121.000 million-$126.000 million vs $124.357 million analyst estimate.

 cellebrite-di-lowers-fy2025-sales-guidance-from-470000m-485000m-to-465000m-475000m-vs-474952m-est

Cellebrite DI (NASDAQ:CLBT) lowers FY2025 sales outlook from $470.000 million-$485.000 million to $465.000 million-$475.000 mil...

 cellebrite-di-q2-adj-eps-012-beats-010-estimate-sales-113276m-beat-112206m-estimate

Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION